QPS Implements LabLogic's DEBRA LIMS
News Sep 10, 2013
QPS has now fully validated LabLogic Debra version 6.0.6 for use in radiolabeled metabolism studies. An earlier version was implemented in 2010 to support discovery stage radiolabel ADME studies. The implementation of Debra LIMS coupled with the recent addition of a high resolution mass spectrometer (HRMS) ensures rapid integration of radioactivity data from mass balance excretion and/or quantitative whole-body autoradiography (QWBA) studies with metabolite identification and radio-quantitation to shorten timelines in support of preclinical and human mass balance studies.
Huw Loaring, PhD., LabLogic’s Systems Director said “There are currently seven sites who have upgraded to Debra 6 and we are very pleased to have worked closely with QPS developing custom-made test scripts for them. QPS is our first contract laboratory to be using this latest release in a fully validated environment.”
Zamas Lam, Ph.D., Senior Vice President & Global Head of Pre-Clinical Development, states “Implementation of a fully validated LIMS will further guarantee data quality, improve efficiency, and provide additional flexibility. As a world class DMPK service provider this type of continuous improvement initiative is paramount to providing unparalleled services to our world-wide customers.”
The Genes That Make Quorn a Fungal Food FavoriteNews
The meat substitute Quorn is derived from a fungus called Fusarium venenatum. A very similar fungus, F. graminearum, is one of the world's most damaging crop diseases. A new genome study shows why one fungus makes food, and the other destroys it.READ MORE
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018